While delta-8-tetrahydrocannabinol (THC) remains a hot topic in the cannabis industry, the discussion about the cannabinoid has shifted to state regulatory talks.
As reported by Hemp Grower, 15 states have already passed delta-8 bans, while six other states have pending laws on cannabinoids and other related THC isomers.
CONNECTED: More states are taking action against Delta-8 THC
Ohio is the next state to follow in the footsteps of Delta-8 regulators as the Ohio Department of Commerce published a series of regulations regarding Delta-8 in medical cannabis products on June 15.
Prior to publication, the Delta-8 content in medicinal cannabis products did not need to be accurately represented on the label. According to the new guidelines, the exact amount of Delta-8 must now be stated on the product label and “Delta-8 THC” must be completely on the packaging; “Delta-8” or “D8” are not allowed.
Breeders, processors and test laboratories must now test for Delta-8 or related THC isomers and analogues and report the results to the department’s inventory tracking system, the guidelines say.
The new regulations also require licensees to provide the Ohio Medical Marijuana Control Program (MMCP) with a Standard Operating Procedure (SOP) that describes how to use Delta-8 in accordance with state code.
Additionally, licensees are now required to run a Delta-8 supply chain through the purchase and production of Delta-8, cannabidiol (CBD), or other ingredients used in the manufacture of medical cannabis.
While some of these regulations are straightforward, some have created confusion among medical cannabis companies, reported Cincinnati.com.
Under the new regulations, the total THC content in medicinal cannabis products cannot exceed 70%, including a combination of Delta-9-THC and other isomers – a change from the division’s original classification of “Total THC” which only Delta -9 contains. reported the news agency.
However, the department argues that the state regulatory cap refers to “tetrahydrocannabinol,” which includes all types of THC, and a spokesperson told Cincinaati.com that the department would soon change its definition in the rules to reflect this.
In addition, the press release states that all regulations for the use of Delta-8 in medical cannabis products are effective immediately; However, the guidelines don’t specify what will happen to the products that are already in inventory or on shelves, the news agency reported.
MMCP stated in the guideline that product safety has top priority. The control program will continue to monitor Delta-8 and other THC isomers during their development, as well as prohibiting product components and providing guidance if necessary.